Molecular mechanisms of uterine leiomyosarcomas: Involvement of defect in LMP2 expression

Gene Regulation and Systems Biology

Volumn 2008, Issue 2, 2008, Pages 297-305

  Hayashi, Takuma ^a,f   Shimamura, Yuto ^a   Saegusa, Taro ^a   Horiuchi, Akiko ^b   Kobayashi, Yukihiro ^c   Hiraoka, Nobuyoshi ^d   Kanai, Yae ^d   Aburatani, Hiroyuki ^e   Sano, Kenji ^c   Konishi, Ikuo ^b  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

IFN signalling pathway; Leiomyosarcoma; lmp2; Uterus

Indexed keywords

GAMMA INTERFERON; LARGE MULTIFUNCTIONAL PROTEASOME; PROTEASOME; UNCLASSIFIED DRUG;

GENETIC TRANSCRIPTION; HUMAN; LEIOMYOSARCOMA; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; PATHOGENESIS; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; UTERUS CANCER;

MUS;

EID: 77953387744     PISSN: None     EISSN: 11776250     Source Type: Journal    
DOI: 10.4137/grsb.s470     Document Type: Review

References (68)

1. Alhopuro, P., Ylisaukko-Oja, S.K., Koskinen, W.J., Bono, P., Arola, J., Jarvinen, H.J., Mecklin, J.P., Atula, T., Kontio, R., Makitie, A.A., Suominen, S., Leivo, I., Vahteristo, P., Aaltonen, L.M. and Aaltonen, L.A. 2005. The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J. Med. Genet., 42:694-8.
2. Anderson, S.E., Nonaka, D., Chuai, S., Olshen, A.B., Chi, D., Sabbatini, P. and Soslow, R.A. 2006. p53, epidermal growth factor, and platelet-derived growth factor i n uterine leiomyosarcoma and leiomyomas. Int. J. Gynecol. Cancer., 16:849-53.
3. Bardelli, A., Parsons, D.W., Silliman, N., Ptak, J., Szabo, S., Saba, S., Markowitz, S., Willson, J.K., Parmigiani, G., Kinzler, K.W., Vogelstein, B. and Velculescu, V.E. 2003. Mutational analysis of the tyrosine kinome in colorectal cancel. Science, 300:949.
4. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, Al, Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. and Green, A.R. 2005. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365:1054-61.
5. Blume-Jensen, P. and Hunter, T. 2001. Oncogenic kinase signalling. Nature, 411:355-65.
6. Bodner-Adler, B., Bodner, K., Kimberger, O., Czerwenka, K., Leodolter, S. and Mayerhofer, K. 2003. MMP-1 and MMP-2 expression in uterine leiomyosarcoma and correlation with different. J. Soc. Gynecol. Investig., 10:443-6.
7. Bodner-Adler, B., Bodner, K., Kimberger, O., Czerwenka, K., Leodolter, S. and Mayerhofer, K. 2004. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. J. Soc. Gynecol. Investig., 11:182-6.
8. Briscoe, J., Rogers, N.C., Witthuhn, B.A., Watling, D., Harpur, A.G., Wilks, A.F., Stark, G.R., Ihle, J.N. and Kerr, I.M. 1996. Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. EAMO J., 15:799-809.
9. Brooks, S.E., Zhan, M., Cote, T. and Baquet, C.R. 2004. Surveillance, epidemiology, and end results an4ysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol. Oncol., 93:204-8.
10. Cabrera, C.M., Jimenez, P., Cabrera, T., Esparza, C., Ruiz-Cabello, F. and Garrido, F. 2003. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 down regulation in MSI-negative tumors. Tissue Antigens, 61:211-9.
11. Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.I., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Harrison, C.N. and Green, A.R. 2005. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366:1945-53.
12. Chapgier, A., Boisson-Dupuis, S., Jouanguy, E., Vogt, G., Feinberg, J., Prochnicka-Chalufour, A., Casrouge, A., Yang, K., Soudais, C., Fieschi, C., Santos, O.F., Bustamante, J., Picard, C., de Beaucoudrey, L., Emile, J.F., Arkwright, P.D., Schreiber, R.D., Rolinck-Werninghaus, C., Rösen-Wolff, A., Magdorf, K., Roesler, J. and Casanova, J.L. 2006. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS. Genet., 2:131.
13. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R. and Futreal, P.A. 2002. Mutations of the BRAF gene in human cancer. Nature, 417:949-54.
14. Dupuis, S., Dargemont, C., Fieschi, C., Thomassin, N., Rosenzweig, S., Harris, J., Holland, S.M., Schreiber, R.D. and Casanova, J.L. 2001. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science, 293:300-3.
15. Dupuis, S., Jouanguy, E., Al-Hajjar, S., Fieschi, C., Al-Mohsen, I.Z., Al-Jumaah, S., Yang, K., Chapgier, A., Eidenschenk, C., Eid, P., Al Ghonaium,A., Tufenkeji, H., Frayha, H., Al-Gazlan, S., Al-Rayes, H., Schreiber, R.D., Gresser, I. and Casanova, J.L. 2003. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet., 33:388-91.
16. Dusenbery, K.E., Potish, R.A. and Judson, P. 2004. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. Gynecol. Oncol., 94:191-6.
17. Dusenbery, K.E., Potish, R.A., Argenta, P.A. and Judson, P.L. 2005. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am. J. Clin. Oncol., 28:295-300.
18. Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N. and Stratton, M.R. 2004. A census of human cancer genes. Nature. Rev. Cancer., 4:177-83.
19. Gadducci, A., Landoni, F., Sartori, E., Zola, P., Maggino, T., Lissoni, A., Bazzurini, L., Arisio, R., Romagnolo, C. and Cristofani, R. 1996. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol. Oncol., 62:25-32.
20. Giuntoli, R.L. and Bristow, R.E. 2004. Uterine leiomyosarcoma: present management. Curr Opin. Oncol., 16:324-7.
21. Haan, S., Margue, C., Engrand, A., Rolvering, C., Schmitz-Van de Leur, H., Heinrich, P.C., Behrmann, I. and Haan, C. 2008. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J. Immunol., 180:998-1007.
22. Hayashi, T. and Faustman, D.L. 2002. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res., 62:24-7.
23. Hayashi, T., Kobayashi, Y., Kohsaka, S. and Sano, K. 2006. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2. Oncogene., 25:4016-26.
24. Hernando, E., Charytonowicz, E., Dudas, M.E., Menendez, S., Matushensky; I., Mills, J., Socci, N.D., Behrendt, N., Ma, L., Maki, R.G., Pandolfi, P.P. and Cordon-Cardo, C. 2007. The AKT-mTOR. pathway plays a critical role in the development of leiomyosarcomas. Nature Med., 13:748-53.
25. Heward, J.M., Allahabadia, A., Sheppard, M.C., Barnett, A.H., Franklyn, J.A. and Gough, S.C. 1999. Association of the large multifunctional proteasome (LMP2) gene with Graves' disease is a result of linkage disequilibrium with the HLA haplotype DRB. 1 *0304-DQB.1*02-DQA1*0501. Clin. Endocrinol., 51:115-8.
26. James, C., Ugo, V., Le Couédic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. and Vainchenker, W. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434:1144-8.
27. Jones, P.A. and Baylin, S.B. 2007. The epigenomics of cancer. Cell, 128:683-92.
28. Kanamori, T., Takakura, K., Mandai, M., Kariya, M., Fukuhara, K., Kusakari, T., Momma, C., Shime, H., Yagi, H., Konishi, M., Suzuki, A., Matsumura, N., Nanbu, K., Fujita, J. and Fujii, S. 2003. PEP-19 overexpression in human uterine leiomyoma. Mol. Hum. Reprod., 9:709-17.
29. Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J. and Schreiber, R.D. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA., 95:7556-61.
30. Kato, K., Shiozawa, T., Mitsushita, J., Toda, A., Horiuchi, A., Nikaido, T., Fujii, S. and Konishi, I. 2004. Expression of the mitogen-inducible gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomas. Hum. Pathol., 35:55-60.
31. Kelley, T.W., Borden, E.C. and Goldblum, J.R. 2004. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl. Immunohistochem. Mol. Morphol., 12:338-41.
32. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. and Skoda, R.C. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med., 352:1779-90.
33. Krämer, U., Illig, T., Grune, T., Krutmann, J. and Esser, C. 2007. Strong associations of psoriasis with antigen processing LMP and transport genes TAP differ by gender and phenotype. Genes Immun., 8:513-7.
34. Larramendy, M.L., Kaur, S., Svarvar, C., Bohling, T. and Knuutila, S. 2006. Gene copy number profiling of soft-tissue leiomyosarcomas by array-comparative genomic hybridization. Can. Cenel. Cylogen., 169:94-101.
35. Lee, J.W., Kim, Y.G., Soung, Y.H., Han, K.J., Kim, S.Y., Rhim, H.S., Min, W.S., Nam, S.W., Park, W.S., Lee, J.Y., Yoo, N.J. and Lee, S.H. 2006. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene., 25:1434-6.
36. Leiser, A.L., Anderson, S.E., Nonaka, D., Chuai, S., Olshen, A.B., Chi, D. S. and Soslow, R.A. 2005. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol. Oncol., 101:86-91.
37. Leitao, M.M., Soslow, R.A., Nonaka, D., Olshen, A.B., Aghajanjan, C., Sabbatini, P., Dupont, J., Hensley, M., Sönoda, Y., Barakat, R.R. and Anderson, S. 2004. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer, 101: 1455-62.
38. Lengyel, E., Sawada, K. and Salgia, R. 2007. Tyrosine kinase mutations in human cancer. Curr. Mol. Med., 7:77-84.
39. Liu, Y., Li, H.J., Qiu, X.T., Guo, H.W., Li, Y.H. and Zhang, Q. 2007. Molecular characterization, expression and mapping of porcine LMP2 and MECL-1 genes. DNA Seq., 18:257-64.
40. Mariani, O., Brennetot, C., Coindre, J.M., Gruel, N., Ganem, C., Delattre, O., Stern, M.H. and Aurias, A. 2007. JUN. Oncogene Amplification and Overexpression Block Adipocytic Differentiation in Highly Aggressive Sarcomas. Cancer Cell, 11:361-74.
41. Mehta, A.M., Jordanova, E.S., van Wezel, T., Uh, H.W., Corver, W.E., Kwappenberg, K.M., Verduijn, W., Kenter, G.G., van der Burg, S.H. and Fleuren, G.J. 2007. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer., 46:577-86,
42. Miettinen, M. and Fetsch, J.F. 2006. Evaluation of biological potential of smooth muscle tumours. Histopathology, 48:97-105.
43. Miyajima, K., Tamiya, S., Oda, Y., Adachi, T., Konomoto, T., Toyoshiba, H., Masuda, K. and Tsuneyoshi, M. 2001. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semiquantitative reverse transcription-polymerase chain reaction. Cancer Lett., 164:177-88.
44. Nordal, R. and Thoresen, S. 1997. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur. J. Cancer, 33:907-11.
45. Pajares, M.J., Ezponda, T., Catena, R., Calvo, A., Pio, R. and Montuenga, L.M. 2007. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol., 8:349-57.
46. Parmar, S. and Platanias, L.C. 2005. Interferons. Cancer Treat. Res., 126:45-68.
47. Parsons, D.W., Wang, T.L., Samuels, Y., Bardelli, A., Cummins, J.M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J.K., Markowitz, S., Kinzler, K.W., Vogelstein, B., Lengauer, C. and Velculescu, V.E. 2005. Colorectal cancer: mutations in a signalling pathway. Nature, 436:792.
48. Perez, E.A., Pusztai, L. and Van de Vijver, M. 2004. Improving patient care through molecular diagnostics. Semin. Oncol., 31:14-20.
49. Platanias, L.C. 2005. Mechanisms of typc-I- and type-II-interferon-mediated signalling. Nature Rev. Immunol., 5:375-86.
50. Ramana, C.V., Gil, M.P., Schreiber, R.D. and Stark, G.R. 2002. Stat1dependent and -independent pathways in IFN-gamma-dependent signaling. Trend Immunol., 23:96-101.
51. Raspollini, M.R., Pinzani, P., Simi, L., Amunni, G., Villanucci, A., Paglierani, M. and Taddei, G.L. 2005. Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT. Gynecol. Oncol., 98:334-5.
52. Rossi, M.R., Hawthorn, L., Platt, J., Burkhardt, T., Cowell, J.K. and Ionov, Y. 2005. Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis. Cancer Genet. Cytogenet., 161:97-103.
53. Satoh, E., Mabuchi, T., Satoh, H., Asahara, T., Nukui, H. and Naganuma, H. 2006. Reduced expression of the transporter associated with antigen processing 1 molecule in malignant glioma cells, and its restoration by interferon-gamma and -beta. J. Neurosurg., 104:264-71.
54. Scarzello, A.J., Romero-Weaver, A.L., Maher, S.G., Veenstra, T.D., Zhou, M., Qin, A., Donnelly, R.P., Sheikh, F. and Gamero, A.M. 2007. A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol. Biol. Cell, 18:2455-62.
55. Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J.C, Williams, I.R., Lee, C.K., Gerthner, R., Kitamura, T., Frantsve, J., Anastasiadou, E., Loh, M.L., Levy, D.E., Ihle, J.N. and Gilliland, D.G. 2000. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/ JAK2. Mol. Cell, 6:693-704.
56. Sexl, V., Kovacic, B., Piekorz, R., Moriggl, R., Stoiber, D., Hoffmeyer, A., Liebminger, R., Kudlacek, O., Weisz, E., Rothammer, K. and Ihle, J.N. 2003. Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood, 101:4937-43.
57. Singal, D.P., Ye, M., Ni, J. and Snider, D.P. 1996. Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines. Immunol. Lett., 50:149-54.
58. Sizemore, N., Agarwal, A., Das, K., Lerner, N., Sulak, M,, Rani, S., Ransohoff, R., Shultz, D. and Stark G.R. 2004. Inhibitor of kappaB. kinase is required to activate a subset of interferon gamma-stimulated genes. Proc. Natl. Acad. Sci. U.S.A., 101:7994-8.
59. Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., Barthorpe, A., Blow, M., Brackenbury, L., Butler, A., Clarke, O., Cole, J., Dicks, E., Dike, A., Drozd, A., Edwards, K., Forbes, S., Foster, R., Gray, K., Greenman, C., Halliday, K., Hills, K., Kosmidou, V., Lugg, R., Menzies, A., Perry, J., Petty, R., Raine, K., Ratford, L., Shepherd, R., Small, A., Stephens, Y., Tofts, C., Varian, J., West, S., Widaa, S., Yates, A., Brasseur, F., Cooper, C.S., Flanagan, A.M., Knowles, M., Leung, S.Y., Louis, D.N., Looijenga, L.H., Malkowicz, B., Pierotti, M.A., The, B., Chenevix-Trench, G., Webet, B.L., Yuen, S.T., Harris, G., Goldstraw, R, Nicholson, A.G., Futreal, P.A., Wooster, R. and Stratton M.R. 2004. Lung cancer: intragemc ERBB2 kinase mutations in tumours. Nature, 431:525-6.
60. Svarvar, C., Larramendy, M.L., Blomqvist, C., Gentile, M., Koivisto-Korander, R., Leminen, A., Butzow, R., Bohling, T. and Knuutila, S. 2006. Do DNA copy number changes differentiate uterine from non-uterine leiomyosarcomas and predict metastasis? Mod. Pathol., 19:1068-82.
61. Tefferi, A., Lasho, T.L. and Gilliland, G. 2005. JAK2 mutations in myelo-proliferative disorders. N. Engl. J. Med., 353:1416-7.
62. Van Kaer, L., Ashton-Rickardt P.G., Eichelberger, M., Gaczynska, M., Nagashima, K., Rock, K.L., Goldberg, A.L., Doherty, P.C. and Tonegawa, S. 1994. Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity, 1:533-41.
63. Wang, L., Felix, J.C., Lee, J.L., Tan, P.Y., Tourgeman, D.E., O'Meara, A.T. and Amezcua, C.A. 2003. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol. Oncol., 90:402-6.
64. Wang, Z., Shen, D., Parsons, D.W., Bardelli, A., Sager, J., Szabo, S., Ptak, J., Silliman, N., Peters, B.A., Van der Heijden, M.S., Parmigiani, G., Yan, H., Wang, T.L., Riggins, G., Powell, S.M., Willson, J.K., Markowitz, S., Kinzler, K.W., Vogelstein, B. and Velculescu, V.E. 2004. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science, 304:1164-6.
65. Wu, T.I., Chang, T.C., Hsueh, S., Hsu, K.H., Chou, H.H., Huang, H.J. and Lai, C.H. 2006. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol. Oncol., 100:166-72.
66. Ylisaukko-oja, S.K., Kiuru, M., Lehtonen, H.J., Lehtonen, R., Pukkala, E., Arola, J., Launonen, V. and Aaltonen, L.A. 2006. Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients. Int. J. Cancer., 119:283-7.
67. Zaloudek, C. and Hendrickson, M.R. 2002. Mesenchymal tumors of the uterus, in Kurman RJ. (ed): Blaustein's Pathology of the Female Genital Tract (ed 5). New York, Springer-Verlag 561-78.
68. Zhai, Y.L., Kobayashi, Y., Mori, A., Orii, A., Nikaido, T., Konishi, I. and Fujii, S. 1999. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int. J. Gynecol. Pathol., 18:20-8.